Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fabio S Macaluso

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
The New England Journal of Medicine|January 12, 2022
Ozanimod for Ulcerative ColitisFabio S Macaluso, Ambrogio Orlando
Minerva Gastroenterologica E Dietologica|October 12, 2019
Anti-TNF combination therapy in inflammatory bowel disease: de novo or selective?Fabio S Macaluso, Ambrogio Orlando
Alimentary Pharmacology & Therapeutics|May 20, 2020
Letter: mesalazine-a safe drug with rare serious adverse eventsBarbara Scrivo, Sara Renna, Angelo Casà, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 7, 2012
Hyperuricaemia: another metabolic feature affecting the severity of chronic hepatitis because of HCV infectionSalvatore Petta, Fabio S Macaluso, Calogero Cammà, et al.
Expert Review of Anticancer Therapy|August 20, 2020
Endoscopic surveillance of colorectal cancer in inflammatory bowel diseases: a review of the literatureAlessandro Vitello, Endrit Shahini, Fabio S Macaluso, et al.
Minerva Gastroenterology|May 31, 2021
Safety and potential interaction of immunosuppressive drugs for the treatment of inflammatory bowel disease in elderly patientsYlenia Ingrasciotta, Mauro Grova, Federica Crispino, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|September 17, 2014
Clinical features and outcomes of patients with drug-induced autoimmune hepatitis: a retrospective cohort studyAnna Licata, Marcello Maida, Daniela Cabibi, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|August 11, 2015
TM6SF2 rs58542926 is not associated with steatosis and fibrosis in large cohort of patients with genotype 1 chronic hepatitis CSalvatore Petta, Marcello Maida, Stefania Grimaudo, et al.
Journal of Clinical Medicine|April 13, 2024
Immune-Mediated Inflammatory Diseases Awareness and Management among Physicians Treating Patients with Inflammatory Bowel Disease: An IG-IBD SurveyMarta Vernero, Cristina Bezzio, Davide G Ribaldone, et al.
JGH Open : an Open Access Journal of Gastroenterology and Hepatology|March 18, 2021
Ustekinumab in Crohn's disease: Real-world outcomes from the Sicilian network for inflammatory bowel diseasesAnna Viola, Marco Muscianisi, Fabio S Macaluso, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
The New England Journal of Medicine|January 12, 2022
Ozanimod for Ulcerative ColitisFabio S Macaluso, Ambrogio Orlando
Minerva Gastroenterologica E Dietologica|October 12, 2019
Anti-TNF combination therapy in inflammatory bowel disease: de novo or selective?Fabio S Macaluso, Ambrogio Orlando
Alimentary Pharmacology & Therapeutics|May 20, 2020
Letter: mesalazine-a safe drug with rare serious adverse eventsBarbara Scrivo, Sara Renna, Angelo Casà, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 7, 2012
Hyperuricaemia: another metabolic feature affecting the severity of chronic hepatitis because of HCV infectionSalvatore Petta, Fabio S Macaluso, Calogero Cammà, et al.
Expert Review of Anticancer Therapy|August 20, 2020
Endoscopic surveillance of colorectal cancer in inflammatory bowel diseases: a review of the literatureAlessandro Vitello, Endrit Shahini, Fabio S Macaluso, et al.
Minerva Gastroenterology|May 31, 2021
Safety and potential interaction of immunosuppressive drugs for the treatment of inflammatory bowel disease in elderly patientsYlenia Ingrasciotta, Mauro Grova, Federica Crispino, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|September 17, 2014
Clinical features and outcomes of patients with drug-induced autoimmune hepatitis: a retrospective cohort studyAnna Licata, Marcello Maida, Daniela Cabibi, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|August 11, 2015
TM6SF2 rs58542926 is not associated with steatosis and fibrosis in large cohort of patients with genotype 1 chronic hepatitis CSalvatore Petta, Marcello Maida, Stefania Grimaudo, et al.
Journal of Clinical Medicine|April 13, 2024
Immune-Mediated Inflammatory Diseases Awareness and Management among Physicians Treating Patients with Inflammatory Bowel Disease: An IG-IBD SurveyMarta Vernero, Cristina Bezzio, Davide G Ribaldone, et al.
JGH Open : an Open Access Journal of Gastroenterology and Hepatology|March 18, 2021
Ustekinumab in Crohn's disease: Real-world outcomes from the Sicilian network for inflammatory bowel diseasesAnna Viola, Marco Muscianisi, Fabio S Macaluso, et al.
Pageof 1